Yield on 10-Year US Treasuries: Highs and Risks https://ymaho.com/yield-on-10-year-us-treasuries-highs-and-risks
Yield on 10-Year US Treasuries Reached 4.60%. Learn How Geopolitics and Inflation Are Changing the Bond Market. Detailed Risk Analysis and Forecasts.
Yield on 30-year US Treasuries at record high https://ymaho.com/yield-on-30-year-us-treasuries-at-record-high
Yield on 30-year US and UK government bonds hits record highs. Find out the reasons for the sell-off, who benefits, and the 90-day forecast. Read the analysis.
Yield on 30-year US Treasuries at 5.2%: risks and forecast https://ymaho.com/yield-on-30-year-us-treasuries-at-5-2-risks-and-forecast
Treasury yield reached 5.2% — a 19-year high. We analyze the causes, consequences for markets, mortgages, and the US economy. Read the 30- and 90-day forecast.
10-year Treasury yield fell to 4.15%: reaction to Powell https://ymaho.com/10-year-treasury-yield-fell-to-4-15-reaction-to-powell
Analysis of the decline in US Treasury yields to 4.15% after Powell's speech. Who won and lost, forecast for 30–90 days. Read the details.
Two-year US Treasury yield hits 15-month high — analysis https://ymaho.com/two-year-us-treasury-yield-hits-15-month-high-analysis
Two-year US Treasury yield jumped to 4.15% on strong employment data. Why does curve steepening signal recession? Full breakdown.
Yield on 10-year US Treasury bonds reached 4.5% https://ymaho.com/yield-on-10-year-us-treasury-bonds-reached-4-5
Analysis of the decline in Treasury prices: why 4.5% is the new normal, how it affects investors and the economy. Read details and forecasts.
Breakthrough in depression treatment: neurosteroids, psilocybin and Caplyta https://ymaho.com/breakthrough-in-depression-treatment-neurosteroids-psilocybin-and-caplyta
FDA approved zuranolone, psilocybin passed phase III, and Caplyta doubles the chance of remission. Learn how moving away from the serotonin theory and new NMDA antagonists are changing psychiatry in 2026.
Saphnelo Pen approved by FDA: treating lupus at home https://ymaho.com/saphnelo-pen-approved-by-fda-treating-lupus-at-home
FDA approved Saphnelo subcutaneous pre-filled pens for lupus treatment. Patients can self-administer the drug without visiting a clinic. Learn about the breakthrough in therapy.
FDA to review CTx-1301 for ADHD treatment in children https://ymaho.com/fda-to-review-ctx-1301-for-adhd-treatment-in-children
New CTx-1301 with trimodal release provides ADHD symptom control for up to 12 hours. Learn about the FDA decision and PTR technology.
US Treasury yield 5%: systemic risk for markets https://ymaho.com/us-treasury-yield-5-systemic-risk-for-markets
Analysis of the reasons for the rise in yield of 30-year US government bonds above 5% and the hidden consequences for global finance. Find out who wins and who loses.